OKYO News

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

OKYO Pharma Announces Public Offering of Ordinary Shares

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

OKYO Pharma Announces Successful Type C Meeting with the FDA

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer